According to Zhitong Finance App, Kang Fang Biotech (09926.HK) announced that the new drug marketing application (SNDA) for first-line treatment of advanced squamous non-small cell lung cancer (SqnsCLC) with the world's first bispecific antibody (PD-1/VEGF) developed by the company has been approved for listing by the China National Drug Administration (NMPA). This is the third indication that Evosi has been approved for marketing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.